

Review

## Gut glucosinolate metabolism and isothiocyanate production

Arjan Narbad<sup>1\*</sup> and John T Rossiter<sup>2</sup>

<sup>1\*</sup> Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, NR4 7UA, UK.

Email arjan.narbad@quadram.ac.uk

<sup>2</sup> Imperial College, Department of Life Sciences, London, SW7 2AZ, UK. Email

jtrossiter@outlook.com

\*Corresponding author

Keywords: gut bacteria, myrosinase, isothiocyanates, glucosinolates, nitriles

### *Abstract*

The glucosinolate-myrosinase system in plants has been well studied over the years while relatively little research has been undertaken on the bacterial metabolism of glucosinolates. The products of myrosinase based glucosinolate hydrolysis in the human gut are important to health particularly the isothiocyanates as they are shown to have anticancer properties as well as other beneficial roles in human health. This review is concerned with the bacterial metabolism of glucosinolates but is not restricted to the human gut. Isothiocyanate production and nitrile formation are discussed together with the mechanisms of the formation of these compounds. Side chain modification of the methylsulfinylalkyl glucosinolates is reviewed and the implications for bioactivity of the resultant products is also discussed.

### *Introduction*

During the cooking process of cruciferous vegetables, myrosinase activity and associated protein specifier proteins are usually destroyed unless strict cooking times are adhered to [1]. Despite the thermal destruction of plant myrosinase activity the intake of cooked *Brassica* vegetables still results in the formation of bioactive isothiocyanates (ITCs) and nitriles which

Received: 29-Nov-2017; Revised: 14-Mar-2018; Accepted: 15-Mar-2018

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/mnfr.201700991](https://doi.org/10.1002/mnfr.201700991).

This article is protected by copyright. All rights reserved.

Accepted Article

arise from the metabolism of glucosinolates (GSLs) by the human gut microbiota. While there is a great deal of information concerning the beneficial effects of GSLs hydrolysis products on human health [2–6] very little is known about the importance of the gut microbiota in generating these bioactive GSL products. Generally there has been little research into the metabolism of GSLs by bacteria particularly those of human origin. The lack of intensity of research into this area of GSLs is surprising as the human gut microbiota acts as a gateway for the formation of these key anticancer metabolites. In order to review the topic, bacteria of extraintestinal origin are also discussed to generate a wider picture of bacterial myrosinases. Table 1 shows work in relation to animal and intestinal models while Table 2 details the work that has been carried out with pure bacterial cultures and includes where known, the GSL substrates and their identified products.

### *Isothiocyanate production*

In general the natural origins of ITCs are from the myrosinase catalyzed hydrolysis (Figure 1) of GSLs [7]. Marine organisms are also known to produce ITCs such as the diterpenoids 10-*epi*-kalinol I and 5-10-bisiosothiocyano kalinol G which have been shown to be biologically active [8]. The functional activity of the ITCs resides in the electrophilic nature of the carbon atom of the  $-N=C=S$  group which is able to undergo addition reactions with various nucleophiles [9, 10]. With amines, thioureas are formed while with sulfhydryl groups dithiocarbamates are the products [9, 10]. Since the diet is complex with a myriad of small molecules it is likely that ITCs react with many nucleophiles and not just with amines or sulfhydryls. The metabolism of ITCs in animal and human cells is *via* the glutathione pathway and is reviewed by other authors in this special edition. To maximise the benefits of ITCs it is of importance to understand how the human gut microbiota metabolises GSLs to ITCs and to what extent these ITCs are further metabolised to form other products that may be more or less bioactive. The gut bacteria play a key role in generating ITCs but these are not always the only end products. Various microbiological studies examining GSL metabolism have been carried out using animals with modified diets and specific microbiotas as well as *in vitro* model fermentation systems inoculated with fecal or cecal bacteria (Table 1). The biotransformation studies with isolated individual bacterial cultures are listed in Table 2. The formation of goiter is a known phenomenon associated with a high intake of cruciferous vegetables in farm animals and humans [11]. One of the first goitrogens to be

discovered was 5-ethenyl-1,3-oxazolidine-2-thione which is derived from 2(*R*)-hydroxy-3-butenylglucosinolate (progoitrin) [12] and was given the name goitrin [13]. Eventually the link between bacterial GSL metabolism and production of goitrin from progoitrin was established [14]. In this study various fecal isolates were tested against progoitrin (Table 2) and *Paracolobactrum aerogenoides* was found to be the most active degrader. The myrosinase activity was also demonstrated in its cell-free protein extract. Further evidence for the involvement of bacteria in GSL metabolism came from work with a *Lactobacillus* strain (LEM220) which was able to degrade GSLs [15] (Table 1). Rats fed a GSL-rich diet with a *Lactobacillus* LEM220 supplement developed goiter in comparison to controls which also confirmed the authors previous work [16]. Further investigations revealed that gnotobiotic rats associated with *E. coli* (EM0) or *Bacteroides vulgatus* (BV8H1) on a rape-seed meal diet developed goiter thus implicating activity of GSL metabolising bacteria [17]. As part of a screen for GSL metabolizing bacteria from human intestinal microbiota, *B. thetaiotaomicron* was isolated and found to convert sinigrin to allylisothiocyanate [18]. This isolate was tested in gnotobiotic rats supplemented with sinigrin and it was found that allylisothiocyanate was produced in the digestive system, thus for the first time linking GSL metabolism with a specific bacterium [19].

Other workers have investigated rat cecal microbiota with a combination of glucoraphanin and bacterial growth media [20]. Here it was found that the rat cecal microbiota produced sulforaphane from GSL but only when supplemented with MRS, the media that supports the growth of *Lactobacilli*. Pretreatment of the rats with glucoraphanin prior to obtaining the cecal contents increased the *ex-vivo* conversion of GSL to ITC suggesting induction of bacterial myrosinase activity.

Brabban and Edwards [21] carried out an extensive study testing some 192 laboratory strains for their ability to metabolise sinigrin. All bacteria that degraded sinigrin in this study were Gram positive and included members of *Streptomyces*, *Bacillus* and *Staphylococcus* derived from different sources (river Mersey, contaminated soil and mushroom compost), however, the products of GLS metabolism by these bacteria were not identified. One of the most well-studied bacterial strains of human gut origin is the Gram positive *Lactobacillus agilis* R16 isolated by Palop et al [22] which produces allylisothiocyanate from sinigrin. The authors could demonstrate myrosinase activity with intact cells but not with cell-free protein extracts. Subsequent studies [23, 24] with *L. agilis* R16 showed similar results with sinigrin except that allylnitrile was also a product. This study was expanded to include glucotropaeolin,

gluconasturtiin, glucoraphanin, glucoerucin and glucoiberin. The activity of *L. agilis* R16 with these GSL substrates showed a degree of substrate specificity as neither glucoraphanin nor glucoiberin were metabolised while gluconasturtiin produced only an ITC. Glucoerucin and glucotropaeolin like sinigrin were converted to ITCs and nitriles [23, 24]. Again it was not possible to demonstrate myrosinase activity with cell-free protein extracts. Further studies were carried out using two bacterial strains *Enterococcus casseliflavus* CP1 and *Escherichia coli* VL8 that originated from human fecal material [23, 24]. *E. coli* VL8 was able to metabolise all the GSLs tested (Table 2) to both nitriles and ITCs in contrast to *L. agilis* R16 which could not metabolise glucoraphanin or glucoiberin. *E. casseliflavus* CP1 was able to metabolise all GSLs tested to nitriles and ITCs with the exception of glucoraphanin and glucoiberin where only trace amounts of ITCs and nitriles were observed. As with *L. agilis* R16, all attempts to identify *in vitro* myrosinase activity in *E. casseliflavus* CP1 and *E. coli* VL8 were unsuccessful. Mullaney et al [25] carried out a study comparing lactic acid bacteria with *Enterobacteriaceae* and in all cases the products of GSL metabolism were nitriles and not ITCs. In this study glucoraphanin and glucoiberin were used and it was found that methylsulfinyl group of the side chain underwent reduction to the methylthio form and this is discussed in more detail later. A study by Lai et al [26] investigated the hydrolysis of glucoraphanin by various *Lactobacilli* in culture media and in all cases the corresponding nitrile was the major metabolic product. Three *Bifidobacteria* strains (*B. pseudocatenulatum*, *B. adolescentis*, *B. longum*) were examined [27] for their ability to biotransform GSLs. All three strains were able to metabolise sinigrin during fermentation while *B. adolescentis* also tested positive for glucotropaeolin metabolism. In the case of *B. adolescentis*, the products of fermentation were allylnitrile and benzyl nitrile while there is less information on the products from *B. pseudocatenulatum* and *B. longum*. The authors carried out further work examining a cell-free protein extract from *B. adolescentis* and found myrosinase activity with the formation of allyl isothiocyanate. Activation by ascorbate was marginal in comparison to plant myrosinases [7]. Attempts to repeat this work with these *Bifidobacteria* strains (RIKEN, Japan Collection of Microorganisms) was not successful in our hands (unpublished data) and may indicate that this trait is either unstable over a period of time or requires an unknown trigger that induces the biosynthesis of the myrosinases in these bacteria.

Luciano et al [28] screened a number of bacteria for their ability to degrade sinalbin and found a various strains including *Lactobacillus curvatus*, *Lactobacillus plantarum*, *Pediococcus pentosaceus*, *Staphylococcus carnosus*, *Staphylococcus aureus* and *E. coli*

0157:H7 to be degraders with the latter being the most active. Further studies involved screening a variety of bacteria including *E. coli* 0157:H7 with sinigrin as a substrate with all strains producing allylthiocyanate [29]. More recent work with the GSL metabolising *E. coli* 0157:H7 identified genes *bglA* and *ascbB* encoding 6-phospho- $\beta$ -glucosidases [30]. Following gene disruption, the sinigrin degrading ability of this organism was substantially reduced. In order to confirm the functional role of these two genes it would be desirable to complement or overexpress these enzymes in the deletion strains.

Recently an isolate from the *Brassica* microbiome has been identified as *Enterobacter cloacae* KS50 and was shown to have myrosinase activity in cell-free protein extracts [31]. The first bacterial myrosinase purification was carried out by Tani et al [32] from *E. cloacae* 506 [33]. The myrosinase was purified to homogeneity by classical chromatography techniques with a molecular weight of 61 kDa. Since this early study only one other bacterial myrosinase has been purified from a *Citrobacter* species (*Citrobacter* Wye1) [34] which has a molecular weight of 66 kDa and was shown to belong to the glycoside hydrolase family 3 (GH3)  $\beta$ -*O*-glucosidases. Cell-free protein extracts produced ITCs although during fermentation, another product was detected but its identity was not established. The *Citrobacter* Wye1 myrosinase has been cloned and successfully expressed in *E. coli* and was shown to be a fully functional enzyme [35].

#### *Nitrile formation*

Cruciferous plants can possess specifier proteins namely epithiospecifier protein (ESP), thiocyanate forming protein (TFP) and nitrile specifier protein (NSP) which direct the myrosinase catalyzed hydrolysis of GSLs to nitriles, epithionitriles and thiocyanates (Figure1) [36]. As part of investigations into the mechanism of these specifier proteins it has been established that ferrous ions play a key role within the active site of the protein during catalysis [37]. While nitriles are readily observed during the hydrolysis of GSLs in fermentation, so far no bacterial specifier proteins have been found/or investigated that promote the formation of nitriles. Interestingly an epithionitrile (ETN) has been observed in only one study [38] (Table 1). In this particular case the substrate was not an intact GSL but DS-sinigrin. As far as we are aware TFP, NSP and ESP like proteins have not been investigated for their ability to modify the products of GSLs or DS-GSLs in bacterial systems. Sulfatases have been identified in many bacteria while few have been cloned and characterized [39, 40]. A detailed study examining the metabolism of five DS-GSLs in

bacterial fermentations has recently been reported [24] where it was shown that specific strains of *E. coli* VL8, *L. agilis* R16 and *E. casseliflavus* CP1 can utilize DS-GSLs as a carbon source and produce nitriles. *L. agilis* R16 and *E. casseliflavus* CP1 however, could not metabolise DS-glucoraphanin while the former was also unable to utilize DS-gluconasturtiin. *E. coli* VL8 could metabolise all DS-GSLs tested to their nitrile derivatives. Another study has shown that a recombinant  $\beta$ -*O*-glucosidase from *Caldocellum saccharolyticum* was able to transform a number of DS-GSLs to their corresponding nitriles in the absence of ferrous ions [41]. This suggests that the origin of nitriles during the fermentation of GSLs may well be a result of desulfation followed by hydrolysis (Figure 2). It is known that plant myrosinases can direct hydrolysis towards nitriles in the presence of ferrous ions without a requirement for a specifier protein [42][43]. A study examining GSLs incubated with the resting cells of *E. coli* VL8 indicated that the presence of ferrous ions shifted hydrolysis away from ITCs towards nitriles [24] suggesting a ferrous ion dependency.

Other work has also shown that a recombinant  $\beta$ -*O*-glucosidase (bgl4) was able to hydrolyse DS-gluconasturtiin to phenethylnitrile without the presence of ferrous ions and on the contrary these ions if present inhibited the hydrolysis [44]. The generation of nitriles from DS-GSLs following hydrolysis by a  $\beta$ -*O*-glucosidase is likely due to the spontaneous decomposition of the thiohydroxamic acid without a need for ferrous ions[45][46]. In order to understand nitrile production during GSL hydrolysis further detailed work is required, particularly the role of ferrous or other metal ion species. In this respect the composition of fermentation media is of importance as the presence of metal ions here can potentially influence the outcome of GSL hydrolysis. Also the observation of an ETN in one study with DS-sinigrin [38] requires following up as the presence of ferrous ions are unlikely to be the only factor in the generation of this nitrile derivative. The fact that amines can be produced during fermentations suggests the presence of bacterial nitrile reductases [47]. These are a relatively new class of enzyme and one has been recently cloned and expressed from *E. coli* K-12 and shown to reduce 7-cyano-7-deazaguanine to amine 7-amino-methyl-7-deazaguanine but has limited substrate specificity [48]. Whether or not bacterial nitrile reductases exist for GSL derived nitriles remains an open question. Nitrilases are well known [49] and it is possible that GSL derived nitriles are further hydrolysed to carboxylic acids thus underestimating the prevalence of nitrile production. GSLs give rise to sulfate and in the presence of ferrous ions will also generate sulfur (Figure 1). In the human gut the sulfate released by GSL hydrolysis is likely to be reduced to hydrogen sulfide by sulfate-reducing

bacteria [50]. Hydrogen sulfide can have negative implications for human health and the importance of the diet and microbiota in this respect is poorly understood. The fate of sulfur derived from GSLs and DS-GSLs in the human gut is unknown but it seems likely that it will undergo reduction to hydrogen sulfide.

#### *Isothiocyanate stability*

As mentioned earlier, the outcome of the bacterial metabolism of GSLs may be influenced by the constituents of the growth media. It is quite possible that metal ions present in media may affect the nature of the products e.g. ferrous ions may shift GSL hydrolysis towards nitriles. Another factor likely to be of importance is the stability of the ITCs in the growth media. Various growth media are utilized depending on the bacteria in question and it is possible that ITCs can react with some of the media components as well as with components of the cell. Previous work has shown ITCs to be unstable in buffers and water [51, 52] while others have determined the half-lives of ITC conjugates [53] which is clearly an important factor to consider when carrying out quantitative determinations of hydrolytic products .

#### *The analysis of glucosinolate metabolites*

Methods for the analysis of GSLs and their hydrolysis products are well reviewed [54] and here we highlight some of the main problems concerning the measurement of GSL metabolites in the gut and fermentation models. During the consumption of *Brassica* vegetables not all of the products of GSLs hydrolysis can be accounted for and ideally the yield of ITCs from an intake of brassica vegetables would be 100% thus enabling the full potential of these health promoting compounds [55]. In this respect the method of analyzing ITCs is important as traditional methods such as GC-MS and LC-MS are likely to underestimate ITC concentrations if significant amounts are bound to protein *via* lysine and cysteine residues. Here, alternative methods that measure total ITCs like the cylocondensation reaction have been used successfully in a study examining the cecal microbiota of rats fed broccoli powder [56]. This was in contrast to LC-MS/DAD and GC-MS analysis where no ITCs were detected. Treatment of the samples with excess glutathione (GSH) however, enabled the ITCs to be observed as their GSH conjugates on the basis that an excess of GSH displaces the ITC from the protein bound conjugates. Methodology has

Accepted Article

been developed for looking at the protein adducts of 1-methoxy-3-indolylmethyl glucosinolate (neoglucobrassicin) metabolites in various organs of mice and this is also potentially a valuable tool in the quantification of ITC protein adducts [57]. The use of isotopically labelled GSLs in studying the metabolism of these compounds in animal models has been very limited. Studies have been carried out with radiolabelled ITCs and 3,4-epithiobutanenitrile where these compounds were fed to rats and their disposition and pharmacokinetics determined [58–60]. While recent advances in LC-MS enables much of the metabolism of GSLs to be followed, there is still a great deal of merit in using both radiolabelled and stable isotopically labelled GSLs. The use of radiolabelled ITCs has given important information on the distribution and pharmacokinetics of these compounds but does not represent the true picture of GSL metabolism particularly in terms of other products such as nitriles.  $^1\text{H}$  NMR has been successfully used to monitor GSL metabolism in a human fecal inoculum during an *in vitro* fermentation [47] and identified two amine products. Figure 4 shows the metabolism of sinigrin by *L. agilis* R16 to give predominantly allylisothiocyanate in real time (unpublished data) using  $^1\text{H}$ -NMR. *In vivo* NMR is a powerful tool [61] to study metabolism yet has been little used in GSL research. With the known synthesis of [ $^{10}\text{-}^{13}\text{C}, 11, 12\text{-}^2\text{H}_5$ ]glucoraphanin [62] it is surprising that this GSL has not been utilized in metabolism work with humans or animal models where there could be scope for *in vivo* NMR spectroscopy. Other radiolabelled GSLs and stable isotopically labelled GSLs have also been synthesised which also would be useful in GSL metabolism studies [63, 64].

#### *Side chain modification*

The range of GSLs tested during fermentations as well the products formed are shown in Table 2. The most commonly examined GSL is sinigrin mostly because of its commercial availability and ease of purification from seed material [65]. Glucoraphanin, however, is increasingly being used in such studies because of its importance to human health. The reduction of sulforaphane to erucin was first observed in a study with rats fed sulforaphane where erucin ITC conjugates were detected in bile and urine [66]. More recently the same type of transformation has been observed with both glucoraphanin and sulforaphane in a human fecal fermentation. During a batch fermentation of glucoraphanin with a human fecal inoculum [67] a time dependent decrease in glucoraphanin concentration was observed with a corresponding increase in the levels of glucoerucin. This was also evident in the hydrolytic



products of the fermentation where sulforaphane and sulforaphane nitrile accounted for less than 2% of the total products while erucin and erucin nitrile formed 28% and 67% respectively. Thus a major change in the side chain structure occurred as well as the formation of nitriles as the dominant products which has implications for the bioactivity of glucoraphanin. Work with individual bacterial strains (Table 2) showed both glucoraphanin and glucoiberin to be converted to their corresponding reduced form to give glucoerucin and glucoiberin while the hydrolytic products were the corresponding nitriles i.e. erucin nitrile and iberin nitrile [25]. Further work [23] with other bacteria showed the same trend with the exception of *L. agilis* R16 and *E. casseliflavus* CP1 which could not metabolise glucoraphanin or glucoiberin while *E. coli* VL8 was able to biotransform both of these GSLs as well as others (Table 2). It was also observed in this study that both sulforaphane and sulforaphane nitrile were able to undergo this conversion to the reduced forms. Using a crude cell-free protein extract of *E. coli* VL8, the reductase activity was shown to be NADPH and  $Mg^{2+}$  dependent. Given the importance of glucoraphanin in the diet, the oxidation-reduction of the methylsulfinyl alkyl side chain requires more work particularly to see if glucoerucin or its corresponding ITC can be re-oxidised in humans.

#### *Bacterial myrosinase sequences and mechanism of activity*

Almost all plant myrosinases belong to the GH1 family of  $\beta$ -*O*-glucosidases and are activated by ascorbate [68–70]. Some insect myrosinases have also been characterised in particular that from *Brevicoryne brassicae* which also belongs to the GH1 family of  $\beta$ -*O*-glucosidases [71–73]. Most interrogation of the bacterial genomes for identification of myrosinase genes have been based on plant myrosinase gene sequences. This was the case for recent work with *E. coli* 0157:H7 where mutations of the putative myrosinase genes were generated by gene replacement to confirm the identify [30]. We have used a similar approach where the candidate genes from *E. casseliflavus* CP1 and *E. coli* VL8 were cloned based on sequences from the known genomes of *E. casseliflavus* NCCP-53 and *E. coli* O83:H1 NRG 857C and overexpressed them in *E. coli* [44] although no myrosinase activity could be demonstrated.

Both plant and aphid myrosinases have been fully characterized [68, 71]. Mechanistically the two enzymes are different with plant myrosinase utilising a glutamic acid as a nucleophile with ascorbate [69] acting as a catalytic base while aphid myrosinase functions as a typical  $\beta$ -*O*-glucosidase using two glutamate residues without a requirement for ascorbate [73]. To date

ascorbate has only had a marginal effect on non-plant myrosinases which is perhaps expected since plant myrosinase utilizes ascorbate as a cofactor in the active site as a base whereas most  $\beta$ -O-glucosidases use a glutamic acid residue.

For bacterial myrosinases, little is known concerning the structure of myrosinase with the exception of *Citrobacter* Wye1 where a complete gene sequence has been identified [34]. This sequence was based on the actual genome of *Citrobacter* Wye1 together with an N-terminal sequence and peptide sequences from tryptic digests of the purified myrosinase. Unlike plant and aphid myrosinases this enzyme belongs to the GH3 family of  $\beta$ -O-glucosidases (InterProt analysis [74]) and the full length myrosinase gene that encodes an N-terminal signal peptide which presumably targets the protein to the periplasm. Other recent work has identified a 6-phospho- $\beta$ -glucosidase (*bglA*, *ascbB*, *chbF*) which was based on homology with plant myrosinase. Gene mutations were carried out and analysed for their ability to metabolise sinigrin and it was found that the genes *bglA* and *ascbB* played an important role in sinigrin degradation by *E. coli* 0157:H7 [30]. It would be useful to express these genes and undertake detailed characterisation to confirm their role as myrosinases. Interestingly the *Citrobacter* Wye 1 myrosinase has strong homology (70%) with an *E. cloacae*  $\beta$ -O-glucosidase which is known to have myrosinase activity as well as high homology with other bacterial  $\beta$ -O-glucosidases. A feature of the GH3  $\beta$ -O-glucosidase is the signature 'SDW' conserved motif as is the case for *Citrobacter* Wye1 myrosinase and contains aspartate as the catalytic nucleophile rather than glutamate that is characteristic of GH1 plant myrosinases. There was very little homology between the *Citrobacter* Wye1 and plant or aphid myrosinases [34]. If a 6-phospho- $\beta$ -glucosidase is responsible for the metabolism of sinigrin by *E. coli* 0157:H7 then it is possible that the GSL substrate requires phosphorylation at the 6-hydroxyl position on the glucose residue of the GSL (Figure 3). ATP-dependent  $\beta$ -glucoside kinases are known and can phosphorylate a range of substrates such as the natural products salicin and amygdalin and artificial substrates like iso-propyl- $\beta$ -D-thioglucopyranoside [75]. In a recent study using differential proteomics on *E. coli* VL8, a glucose specific phosphotransferase system was shown to be induced by sinigrin (in comparison to a control) which gives some evidence towards a phosphorylation step necessary for the hydrolysis of GSLs [76]. Thus, a prerequisite phosphorylation of the glucose moiety might explain why it has not been possible to observe myrosinase activity in cell-free protein extracts of some of the bacteria such as *L. agilis* R16 described in this review.

### *Diversity of microorganisms able to metabolise glucosinolates*

Despite the limited number of studies on bacterial metabolism of GSLs it is clear that this metabolic capacity is not limited to a single phylotype or a family of bacterial species. They include members of Firmicutes, Bacteroidetes, Actinomycetes and Proteobacteria. There is good evidence to indicate that a high degree of horizontal gene transfer can occur between bacterial species in the environment [77, 78] that may explain the observed diversity in bacterial groups able to metabolise the GSLs. The range of bacteria include both Gram positive and Gram negative, those that are rods or cocci, commensal and those associated with pathogenic traits all have the capacity for GSL biotransformation. Also, the habitat of these bacteria is not limited to the GI tract although most of the studies are related to gut bacteria for their association with dietary GSLs. They are also found in soil and have been isolated from plant sources. No doubt we will find many more relevant bacterial groups as we learn more about the gut bacteria and their metabolic capacity in both human and animal GI tract. In this review, we have focused only on bacterial metabolism but it is highly likely that in time we will discover other microbes, archaea, yeast and fungi that are able to metabolise GSLs. Several studies have already reported the presence of myrosinase in *Aspergillus niger* [79, 80] and other fungi [81, 82].

### *Conclusions and future work*

In comparison to plants very little work has been carried out on the metabolism of GSLs by bacteria. Given the importance of GSLs in the human diet it has become desirable to investigate the mechanisms of their biotransformation in the gut particularly with a view to increasing ITC production. This requires a much more detailed study to identify those bacteria that play a key role in ITC production as well as investigating why nitriles are often the end- products. It may well be that ITCs are toxic to the bacteria that produce them and it then becomes preferable for NIT production as a form of detoxification as is the case for some insects that metabolise GSLs [83]. While specifier proteins that modify the outcome of GSL hydrolysis have been discovered in plants [36] no such proteins have been found in bacteria although there is one case of an identified ETN in rat intestinal microbiota [38] which suggests the presence of an ESP-like protein although this requires confirmation. The

role of sulfatases in GSL metabolism is still unclear although DS-GSL metabolism to nitriles has been established and these enzymes require identification to confirm this role.

Human intervention studies have shown that there is a wide variation in the amount of ITC present in the urine and it is thought that this may reflect on differences in the composition of the microbiota of individuals i.e. the ability of microbiota to generate ITCs [84, 85]. These studies identified subjects that are low or high secretors of ITCs in their urine and indeed the fecal microbiota of high ITC secretors were more efficient at degrading glucoraphanin than those of low ITC secretors. However, using tRFLP, a relatively low resolution molecular profiling method, indicated that the gut bacterial communities are altered by consumption of cruciferous vegetables in all subjects. It was not possible however, to differentiate the composition of the gut microbiota between the two secretor groups [84, 85]. Given that many of the identified metabolisers of the GSLs include groups of beneficial bacteria such as the lactobacilli and bifidobacteria that are often utilised as probiotics, this opens up potential opportunities to exploit such bacteria as dietary supplements with GSL containing foods that would provide health benefits particularly to low ITC secreting individuals as part of their personalized nutrition. Recently a study has looked at the potential for expressing the glucotropaeolin biosynthetic pathway in *E. coli* together with a myrosinase of *B. brevicoryne* with some success as the authors were able to show the *in vitro* formation of benzylisothiocyanate [86]. If this technology can be developed where ITCs are actually produced during fermentation then it could potentially allow the delivery of sulforaphane in the gut. However, such heterologous systems would be considered GMO and would require regulatory approval.

Further characterization of bacterial myrosinases should be an important goal in understanding product formation from GSL hydrolysis. The sequences of bacterial myrosinase genes are likely to be different from plant and aphid myrosinases as was demonstrated by the recent characterisation of the *Citrobacter* Wye1 enzyme [34]. Once additional functional bacterial genes have been identified it will open up opportunities for genome mining of human and animal gut bacterial metagenomes which are becoming widely available as a result many different microbiome sequencing projects. Approaches to identify myrosinase genes should include the determination of genomes together with peptide sequence analysis of partially or purified myrosinase. A synthesis of 6-P-GSL would enable the possibility of 6-phospho- $\beta$ -*O*-glucosidases as myrosinases to be explored. *L. agilis* R16 produces large amounts of allylisothiocyanate from sinigrin yet does not inhibit its growth

suggesting that the ITC cannot cross its cell wall or it has developed other resistance mechanisms. In contrast, *Citrobacter* Wye1 does not seem to produce allylithiocyanate *in vivo* but to as yet an unknown molecule which might be a detoxification product or that the allylithiocyanate is unstable. This may also be true of other bacteria and requires a more thorough study to determine potential detoxification mechanisms. For example allylamine and benzylamine were obtained from sinigrin and glucotropaeolin respectively in a human fecal fermentation [47]. During our fermentation work, both with pure bacterial cultures and with mixed fecal bacteria we have never observed amines and it would be desirable to investigate further the occurrence of these compounds.

Of interest is the effect that ITC producing bacteria have on other microorganisms of the human gut. ITCs are known to have antibacterial properties [87–89] and it is possible that there may be an overall negative effect on other functions of the gut microbiota. This however, would be dependent on the concentrations of ITCs in the human gut and as yet this question has not been fully addressed [56]. A recent study has shown that the microbial conversion of GSLs to ITCs can be modified by the frequency of GSL consumption in rats and resulted in a change of the microbiota composition [90] which is effectively an enrichment process for GSL utilizing bacteria. While some bacteria produce ITCs it is highly likely that other bacteria in the human gut will have the potential to detoxify these compounds so the situation with the microbiota is likely to be complex. This raises many questions on the importance and efficiency of gut bacteria in the generation of ITCs and competing detoxification processes and how this impacts on the bioavailability of ITCs.

#### *Acknowledgements*

This work was supported by UK Biotechnology and Biological Sciences Research Council [BB/J004545/1]. We thank Melanie Chu and Joe Bundy for provision of Figure 4. The authors have declared no conflicts of interest.

#### *References*

- [1] N. V. Matusheski, R. Swarup, J. A. Juvik, R. Mithen, M. Bennett, E. H. Jeffery, *J. Agric. Food Chem.* **2006**, *54*, 2069.
- [2] N. Fujioka, V. Fritz, P. Upadhyaya, F. Kassie, S. S. Hecht, *Mol. Nutr. Food Res.* **2016**, *60*, 1228.

- [3] A. Mazumder, A. Dwivedi, J. Du Plessis, *Molecules* **2016**, *21*, DOI 10.3390/molecules21040416.
- [4] P. Gupta, B. Kim, S. H. Kim, S. K. Srivastava, *Mol. Nutr. Food Res.* **2014**, *58*, 1685.
- [5] J. D. Hayes, M. O. Kelleher, I. M. Eggleston, *Eur. J. Nutr.* **2008**, *47*, 73.
- [6] M. Traka, R. Mithen, *Phytochem. Rev.* **2009**, *8*, 269.
- [7] A. M. Bones, J. T. Rossiter, *Physiol. Plant.* **1996**, *97*, 194.
- [8] M. J. Garson, J. S. Simpson, *Nat. Prod. Rep.* **2004**, *21*, 164.
- [9] S. Patai, *The Chemistry of Cyanates and Their Thio Derivatives*, **2010**.
- [10] K. K. Brown, M. B. Hampton, *Biochim. Biophys. Acta - Gen. Subj.* **2011**, *1810*, 888.
- [11] G. R. Fenwick, R. K. Heaney, W. J. Mullin, *Crit. Rev. Food Sci. Nutr.* **1983**, *18*, 123.
- [12] M. A. Greer, *J. Am. Chem. Soc.* **1956**, *78*, 1260.
- [13] E. B. Astwood, M. A. Greer, M. G. Ettliger, *J. Biol. Chem.* **1949**, *181*, 121.
- [14] E. L. Oginsky, A. E. Stein, M. A. Greer, *Exp. Biol. Med.* **1965**, *119*, 360.
- [15] L. Nugon- Baudon, S. Rabot, J. - M Wal, O. Szytit, *J. Sci. Food Agric.* **1990**, *52*, 547.
- [16] L. Nugon- Baudon, O. Szytit, P. Raibaud, *J. Sci. Food Agric.* **1988**, *43*, 299.
- [17] S. Rabot, L. Nugon-Baudon, P. Raibaud, O. Szytit, *Br. J. Nutr.* **1993**, *70*, 323.
- [18] S. Rabot, C. Guerin, L. Nugon-Baudon, O. Szytit, in *Proc. 9th Int. Rape-Seed Congr. (GCIRC, Ed.)*, Dorset Press, Dorchester, **1995**, pp. 212–214.
- [19] L. Elfoul, S. Rabot, N. Khelifa, A. Quinsac, A. Duguay, A. Rimbault, *FEMS Microbiol. Lett.* **2001**, *197*, 99.
- [20] R.-H. Lai, M. J. Miller, E. Jeffery, *Food Funct.* **2010**, *1*, 161.
- [21] A. . Brabban, C. Edwards, *FEMS Microbiol. Lett.* **1994**, *119*, 83.
- [22] M. Ll. Palop, J. P. Smiths, B. ten Brink, *Int. J. Food Microbiol.* **1995**, *26*, 219.
- [23] V. Luang-In, A. Narbad, C. Nueno-Palop, R. Mithen, M. Bennett, J. T. Rossiter, *Mol.*

- Nutr. Food Res.* **2014**, *58*, 875.
- [24] V. Luang-In, A. A. Albaser, C. Nueno-Palop, M. H. Bennett, A. Narbad, J. T. Rossiter, *Curr. Microbiol.* **2016**, *73*, 442.
- [25] J. A. Mullaney, W. J. Kelly, T. K. McGhie, J. Ansell, J. A. Heyes, *J. Agric. Food Chem.* **2013**, *61*, 3039.
- [26] R.-H. Lai, M. J. Miller, E. H. Jeffery, *FASEB J.* **2009**, *23*.
- [27] D. L. Cheng, K. Hashimoto, Y. Uda, *Food Chem. Toxicol.* **2004**, *42*, 351.
- [28] F. B. Luciano, J. Belland, R. A. Holley, *Int. J. Food Microbiol.* **2011**, *145*, 69.
- [29] S. Herzallah, M. L. Lledó, R. Holley, *J. Food Prot.* **2011**, *74*, 2162.
- [30] R. P. Cordeiro, J. H. Doria, G. G. Zhanel, R. Sparling, R. A. Holley, *Int. J. Food Microbiol.* **2015**, *205*, 105.
- [31] B. Wassermann, D. Rybakova, C. Müller, G. Berg, *Sci. Rep.* **2017**, *7*, DOI 10.1038/s41598-017-17949-z.
- [32] N. Tani, M. Ohtsuru, T. Hata, T. Naoki, T. Ani, *Agr. Biol. Chem* **1974**, *389*, 1623.
- [33] N. Tani, M. Ohtsuru, T. Hata, *Agric. Biol. Chem.* **1974**, *38*, 1617.
- [34] A. Albaser, E. Kazana, M. H. Bennett, F. Cebeci, V. Luang-In, P. D. Spanu, J. T. Rossiter, *J. Agric. Food Chem.* **2016**, *64*, 1520.
- [35] F. Cebeci, The Metabolism of Plant Glucosinolates by Gut Bacteria, University of East Anglia, **2017**.
- [36] J. C. Kuchernig, M. Burow, U. Wittstock, *BMC Evol. Biol.* **2012**, *12*, 127.
- [37] W. Brandt, A. Backenköhler, E. Schulze, A. Plock, T. Herberg, E. Roese, U. Wittstock, *Plant Mol. Biol.* **2014**, *84*, 173.
- [38] M. Lu, K. Hashimoto, Y. Uda, *Food Res. Int.* **2011**, *44*, 1023.
- [39] P. Gadler, K. Faber, *Trends Biotechnol.* **2007**, *25*, 83.
- [40] S. R. Hanson, M. D. Best, C. H. Wong, *Angew. Chemie - Int. Ed.* **2004**, *43*, 5736.

- [41] J. P. Wathélet, R. Iori, O. Leoni, P. Rollin, N. Mabon, M. Marlier, S. Palmieri, *Biotechnol. Lett.* **2001**, *23*, 443.
- [42] A. J. MacLeod, J. T. Rossiter, *Phytochemistry* **1986**, *25*, 1047.
- [43] F. L. Austin, C. Gent, I. Wolff, *Can. J. Chem.* **1968**, *46*, 1507.
- [44] V. Luang-In, Influence of Human Gut Microbiota on the Metabolic Fate of Glucosinolates, Imperial College, **2013**.
- [45] J. Kopycki, J. Schmidt, S. Abel, C. D. Grubb, *Biotechnol. Lett.* **2011**, *33*, 1039.
- [46] M. G. Ettliger, A. J. Lundeen, *J. Am. Chem. Soc.* **1957**, *79*, 1764.
- [47] B. Combourieu, L. Elfoul, A. M. Delort, S. Rabot, *Drug Metab. Dispos.* **2001**, *29*, 1440.
- [48] K. Moeller, G. S. Nguyen, F. Hollmann, U. Hanefeld, *Enzyme Microb. Technol.* **2013**, *52*, 129.
- [49] P. W. Ramteke, N. G. Maurice, B. Joseph, B. J. Wadher, *Biotechnol. Appl. Biochem.* **2013**, *60*, 459.
- [50] F. Carbonero, A. C. Benefiel, A. H. Alizadeh-Ghamsari, H. R. Gaskins, *Front. Physiol.* **2012**, *3 NOV*, DOI 10.3389/fphys.2012.00448.
- [51] V. Luang-In, J. T. Rossiter, *Songklanakarin J. Sci. Technol.* **2015**, *37*, 625.
- [52] J. R. Mays, R. L. W. Roska, S. Sarfaraz, H. Mukhtar, S. R. Rajski, *ChemBioChem* **2008**, *9*, 729.
- [53] A. A. Al Janobi, R. F. Mithen, A. V. Gasper, P. N. Shaw, R. J. Middleton, C. A. Ortori, D. A. Barrett, *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2006**, *844*, 223.
- [54] D. B. Clarke, *Anal. Methods* **2010**, *2*, 310.
- [55] D. Angelino, E. Jeffery, *J. Funct. Foods* **2014**, *7*, 67.
- [56] D. Angelino, E. B. Dosz, J. Sun, J. L. Hoeflinger, M. L. Van Tassell, P. Chen, J. M. Harnly, M. J. Miller, E. H. Jeffery, *Front. Plant Sci.* **2015**, *6*, DOI



- 10.3389/fpls.2015.00831.
- [57] G. Barknowitz, W. Engst, S. Schmidt, M. Bernau, B. H. Monien, M. Kramer, S. Florian, H. Glatt, *Chem. Res. Toxicol.* **2014**, *27*, DOI 10.1021/tx400277w.
- [58] C. C. Conaway, D. Jiao, T. Kohri, L. Liebes, F. L. Chung, *Drug Metab. Dispos.* **1999**, *27*, 13.
- [59] M. Bollard, S. Stribbling, S. Mitchell, J. Caldwell, *Food Chem. Toxicol.* **1997**, *35*, 933.
- [60] E. R. Brocker, M. H. Benn, J. Lüthy, A. von Däniken, *Food Chem. Toxicol.* **1984**, *22*, 227.
- [61] J. Valette, B. Tiret, F. Boumezbeur, *Anal. Biochem.* **2017**, *529*, DOI 10.1016/j.ab.2016.08.003.
- [62] J. J. Morrison, N. P. Botting, *Tetrahedron Lett.* **2007**, *48*, 1891.
- [63] S. Chevolleau, B. Joseph, P. Rollin, J. Tulliez, *J. Labelled Comp. Radiopharm.* **1993**, *33*, 671.
- [64] J. T. Rossiter, J. A. Pickett, M. H. Bennett, A. M. Bones, G. Powell, J. Cobb, *Phytochemistry* **2007**, *68*, 1384.
- [65] W. Thies, *FETT Wiss. Technol. Sci. Technol.* **1988**, *90*, 311.
- [66] K. Kassahun, M. Davis, P. Hu, B. Martin, T. Baillie, *Chem. Res. Toxicol.* **1997**, *10*, 1228.
- [67] S. Saha, W. Hollands, B. Teucher, P. W. Needs, A. Narbad, C. A. Ortori, D. A. Barrett, J. T. Rossiter, R. F. Mithen, P. A. Kroon, *Mol. Nutr. Food Res.* **2012**, *56*, 1906.
- [68] W. P. Burmeister, S. Cottaz, H. Driguez, R. Iori, S. Palmieri, B. Henrissat, *Structure* **1997**, *5*, 663.
- [69] W. P. Burmeister, S. Cottaz, P. Rollin, A. Vasella, B. Henrissat, *J. Biol. Chem.* **2000**, *275*, 39385.
- [70] A. M. Bones, J. T. Rossiter, *Physiol. Plant.* **1996**, *97*, 194.

- [71] H. Husebye, S. Arzt, W. P. Burmeister, F. V. Härtel, A. Brandt, J. T. Rossiter, A. M. Bones, *Insect Biochem. Mol. Biol.* **2005**, *35*, 1311.
- [72] A. M. E. Jones, M. Bridges, A. M. Bones, R. Cole, J. T. Rossiter, *Insect Biochem. Mol. Biol.* **2001**, *31*, 1.
- [73] A. M. E. Jones, P. Winge, A. M. Bones, R. Cole, J. T. Rossiter, *Insect Biochem. Mol. Biol.* **2002**, *32*, 275.
- [74] P. Jones, D. Binns, H. Y. Chang, M. Fraser, W. Li, C. McAnulla, H. McWilliam, J. Maslen, A. Mitchell, G. Nuka, S. Pesseat, A. F. Quinn, A. Sangrador-Vegas, M. Scheremetjew, S. Y. Yong, R. Lopez, S. Hunter, *Bioinformatics* **2014**, *30*, 1236.
- [75] J. Thompson, F. W. Lichtenthaler, S. Peters, A. Pikis, *J. Biol. Chem.* **2002**, *277*, 34310.
- [76] V. Luang-In, A. Narbad, F. Cebeci, M. Bennett, J. T. Rossiter, *Protein J.* **2015**, *34*, 135.
- [77] C. S. Smillie, M. B. Smith, J. Friedman, O. X. Cordero, L. A. David, E. J. Alm, *Nature* **2011**, *480*, 241.
- [78] J. H. Hehemann, G. Correc, T. Barbeyron, W. Helbert, M. Czjzek, G. Michel, *Nature* **2010**, *464*, 908.
- [79] M. Ohtsuru, I. Tsuruo, T. Hata, *Agric. Biol. Chem.* **1973**, *37*, 967.
- [80] M. Ohtsuru, T. Hata, *Agric. Biol. Chem.* **1973**, *37*, 2543.
- [81] J. P. Smits, W. Knol, J. Bol, *Appl. Microbiol. Biotechnol.* **1993**, *38*, 696.
- [82] S. Galletti, E. Sala, O. Leoni, S. Cinti, C. Cerato, *Soil Biol. Biochem.* **2008**, *40*, 2170.
- [83] V. Jeschke, J. Gershenzon, D. G. Vassão, in *Form. Struct. Act. Phytochem.*, **2015**, pp. 163–194.
- [84] F. Li, M. A. J. Hullar, Y. Schwarz, J. W. Lampe, *J. Nutr.* **2009**, *139*, 1685.
- [85] F. Li, M. A. J. Hullar, S. A. A. Beresford, J. W. Lampe, *Br. J. Nutr.* **2011**, *106*, 408.
- [86] F. Liu, H. Yang, L. Wang, B. Yu, *ACS Synth. Biol.* **2016**, *5*, 1557.
- [87] A. C. Abreu, A. Borges, L. C. Simoes, M. J. Saavedra, M. Simoes, *Med. Chem. (Los.*

*Angeles*). **2013**, *9*, 756.

- [88] A. Borges, A. C. Abreu, C. Ferreira, M. J. Saavedra, L. C. Simões, M. Simões, *J. Food Sci. Technol.* **2015**, *52*, 4737.
- [89] A. Aires, V. R. Mota, M. J. Saavedra, E. A. S. Rosa, R. N. Bennett, *J. Appl. Microbiol.* **2009**, *106*, 2086.
- [90] X. Liu, Y. Wang, J. L. Hoeflinger, B. P. Neme, E. H. Jeffery, M. J. Miller, *Nutrients* **2017**, *9*, DOI 10.3390/nu9030262.
- [91] C. Krul, C. Humblot, C. Philippe, M. Vermeulen, M. van Nuenen, R. Havenaar, S. Rabot, *Carcinogenesis* **2002**, *23*, 1009.
- [92] J. Huber, G. Kranz, G. Kreibich, K. Beining, M. Kruger, F. Weissbach, *Nahrung* **1983**, *27*, 257.
- [93] A. N. Olaima, B. Sobhi, R. A. Holley, *J. Food Prot.* **2014**, *77*, 2133.

*Figure Legends*

Figure 1. Generalised scheme of the hydrolysis of GSLs by plant myrosinases. RNCS, isothiocyanate; RCN, nitrile; RSCN, thiocyanate; ETN, epithionitriles; ESP, epithiospecifier protein; TFP, thiocyanate forming protein.





Figure 2. Hypothesised route to nitriles *via* DS-GSLs

Figure 3. Generalised structure of a hypothetical 6-P-glucosinolate





Figure 4. The metabolism of sinigrin monitored by  $^1\text{H}$ -NMR over 19 h showing the changes in the proton resonances of the alkenyl region of sinigrin and allylthiocyanate during metabolism.  $^1\text{H}$ -NMR was carried out on a Bruker Avance DRX600 spectrometer, 14.1 T magnet and 600MHz proton resonance frequency.



## Graphic Abstract

Gut bacteria play an important role in the hydrolysis of dietary glucosinolates to the isothiocyanates that are known to have chemoprotective functions. We have yet to fully characterise all the bacterial enzymes involved. In the GI tract this hydrolytic process appears complex and a number of bacterial metabolic pathways are proposed that result in the production of isothiocyanates or nitrile products.






Table 1: *In vivo* and *in vitro* fermentations. GSLs used as substrates; 1, sinigrin; 2, glucotrapaeolin; 4, glucoraphanin; 5, glucoerucin (\* from *in vitro* interconversion of glucoraphanin to glucoerucin). Products 9, allylisothiocyanate; 10, allylnitrile; 15, sulforaphane; 16, sulforaphane nitrile; 19, erucin; 20, erucin nitrile; 22, 3,4-epithiobutanenitrile (3,4-epithiobutanenitrile); 23, allylamine; 24, benzylamine. NT, not tested; NA, not available; ND, not detected; OP, other product.

	Analysis						Ref
	DS-GSL	GSL	ITC	NIT	OP	% conversion of GSL/ DS-GSL (time)	
Rat- diet supplemented with <i>B. thetaiotaomicron</i> .		1	9	ND		100 (36 h)	[19]
Rat cecal microbiota		4	ND	trace		100 (24 h)	[20]
Cecal microbiota with MRS media		4	15	trace		39 (24 h)	
Human fecal inoculum in media supplemented with		1	ND	ND	23	100 (30 h)	[47]
		2	ND	ND	24	100 (30 h)	
Human <i>in vitro</i> intestinal model		1	9	ND		100 (12 h)	[91]
Human <i>in vitro</i> intestinal model		4	15	16	60 (24 h)	(based on combined concentration of GSL 4 & 5)	[67]
Rat intestinal microbiota		1	9	10		69 (6 h)	[38]
	1	RSM	9 (trace)	10	22		
<i>Lactobacillus</i> (LEM 220) Rats		RSM	NT	NT		NA	[15]
<i>E. Coli</i> (EM0)							

<i>Bacteroides vulgatus</i> (BV8H1)		RSM	NT	NT		NA	[17]
-------------------------------------	--	-----	----	----	--	----	------

Table 2: *In vitro* assessment of pure bacterial strains shown to metabolise GSLs. The presence or absence of the typical products i.e. ITC and/or nitrile are indicated. % GSL conversion is given as the least to the maximum value for any number of isolates, NT = not tested, NA = not available, ND = not detectable. Myr+ = myrosinase activity, Myr- = no myrosinase activity. GSLs used as substrates; 1, sinigrin; 2, glucotropaeolin; 3, gluconasturtiin; 4, glucoraphanin; 5, glucoerucin; 6, glucoiberin; 7, sinalbin; 8, progoitrin. Products; 9, allylisothiocyanate; 10, allylnitrile; 11, benzyl nitrile; 12, benzylisothiocyanate; 13, phenethyl nitrile; 14, phenethylisothiocyanate; 15, sulforaphane; 16, sulforaphane nitrile; 17, iberberin; 18, iberberin nitrile; 19, erucin; 20, erucin nitrile; 21, goitrin. RSM = rape seed meal GSL extract products i.e. ITC and/or nitrile are indicated. 1, DS-sinigrin; 2, DS-glucotropaeolin; 3, DS-gluconasturtiin; 4, DS- glucoraphanin; 5, DS-glucoerucin. Products: 10, allylnitrile; 11, benzyl nitrile; 13, phenethyl nitrile; 16, sulforaphane nitrile; 20, erucin nitrile.

Bacterial species	Gram +/-	Fermentation				Cell free protein extract			
		GSL	ITC	NIT	% GSL conversion 24 h (unless specified).	GSL	ITC Myr+ Myr-	NIT	Ref
<i>Citrobacter</i> WYE1	-	1	ND	ND	100	1,2,3,4	9, Myr+	ND	[34]
<i>Bacillus</i> (isolates)	+	1	NT	NT	74/91/62/56	NT			[21]
<i>Pseudomonas</i>	-	1	NT	NT	NA	NT			[21]
<i>Lactobacillus</i>	+	1	NT	NT	NA	NT			[21]
<i>Lactobacillus</i> (LEM)	+	1	NT	NT	13-28 (5 d)	NT			[15]
		8	NT	NT	13-20 (5 d)	NT			[15]

<i>Streptomyces</i> (isolates)	+	1	NT	NT	43-67	NT			[21]
<i>Staphylococcus</i>	+	1	NT	NT	77	NT			[21]
<i>Lactobacillus agilis</i> R16	+	1	9	10	100	1	Myr-		[22, 24]
		5	19	20	100	NT			[23]
		6	ND	ND	11	NT			[23]
		4	ND	ND	10	NT			[23]
		2	12	11	90	NT			[24]
		3	14	ND	95	NT			[24]
<i>Enterococcus</i> <i>casseliflavus</i> CP1	+	1	9	10	100	1	Myr-		[24]
		5	19	20	100	NT			[23]
		6	trace	ND	41	NT			[23]
		4	ND	trace	53	NT			[23]
		2	12	11	90	NT			[24]
		3	14	13	100	NT			[24]
<i>Escherichia coli</i> VL8	-	1	9	10	90	1	Myr-		[24]
		5	19	20	100	NT			[23]
		6	17	18	87	NT			[23]
		4	15	16	91	NT			[23]
		2	12	11	100	NT			[24]
		3	14	13	100	NT			[24]
		Fermentation				Cell free protein extract			
<i>Lactobacillus</i> <i>plantarum</i> KW30	+	4,6	ND	16,18,20	30-33	NT			[25]
<i>Lactococcus lactis</i> . <i>Subsp. Lactis</i> KF147	+	4,6	ND	16,18,20	30-33	NT			[25]

<i>Escheria coli</i> Nissle 1917	-	4,6	ND	16,18	65-78	NT			[25]
<i>Enterobacter cloacae</i>	-	4,6	ND	16,18	65-78	NT			[25]
<i>Enterobacter cloacae</i>	-	1	NT	NT	100 (24-48 h)	1	Myr +		[33]
<i>Enterobacter cloacae</i> KS50	-	1	NT	NT	NA	1	Myr +		[31]
<i>Bacillus cereus</i> 10X	+	RSM	21	NT	NA	NT			[92]
<i>Bacillus cereus</i> St3									
<i>Lactobacillus gasseri</i>	+	4	ND	16	36-49	NT			[26]
<i>Lactobacillus acidophilus</i>	+	4	ND	16	36-49	NT			[26]
<i>Lactobacillus casei</i>	+	4	ND	16	36-49	NT			[26]
<i>Lactobacillus plantarum</i>	+	4	ND	16	36-49	NT			[26]
<i>Bifidobacterium pseudocatenulatum</i>	+	1,2	NT	NT	73-83 (48 h) for all strains for	NT			[27]
<i>Bifidobacterium adolescents</i>	+	1	ND	10	GSL		9		[27]
<i>Bifidobacterium adolescents</i>		2	ND	11	(1). 84 (48 h) for	NT			[27]
<i>Bifidobacterium longum</i>	+	1,2	ND	NT	<i>B. adolescents</i> with GSL (2)	NT			[27]
<i>Bacteroides thetaiotaomicron</i> (II8)	-	1	9	ND	100 (36 h)	NT			[19]
<i>E. coli</i> (various strains)	-	8	21	NT	3-26 (48 h)	NT			[14]
<i>Paracolobactrum aerogenoides</i>	-	8	21	NT	24-81 (48 h)	8	21	NT	[14]

<i>Aerobacter aerogenes</i>	+	8	21	NT	26-28 (48 h)	NT			[14]
<i>Bacillus subtilis</i>	+	8	21	NT	59-72 (48 h)	NT			[14]
<i>Staphylococcus epidermis</i>	+	8	21	NT	19 (48 h)	NT			[14]
<i>Proteus vulgaris</i>	-	8	21	NT	42-48 (48 h)	NT			[14]
<i>E. coli</i> 0157:H7	-	1	9	NT	12 (5 d)	NT			[30]
<i>Lactobacillus curvatus</i> (various strains)	+	7	NT	NT	2.4-5.4 (6 d)	NT			[28]
<i>Lactobacillus plantarum</i> (various strains)	+	7	NT	NT	0.6-4 (6 d)	NT			[28]
		Fermentation				Cell free protein extract			
<i>Pediococcus pentosaceus</i> (various strains)	-	7	NT	NT	5.02-11.3 (6 d)	NT			[28]
<i>Staphylococcus carnosus</i> (various strains)	+	7	NT	NT	6.06-10 (6 d)	NT			[28]
<i>Pediococcus acidilactici</i>	+	7	NT	NT	2.92-3.16 (6 d)	NT			[28]
<i>Pediococcus pentosaceus</i>	+	1	9	NT	11.99 (12 d)	NT			[29]
<i>E. coli</i> 0157:H7	-	1	9	NT	38.96 (12 d)	NT			[29]
<i>Listeria monocytogenes</i>	+	1	9	NT	19.04 (8 d)	NT			[29]
<i>Escherichia fecalis</i>	+	1	9	NT	9.05 (12 d)	NT			[29]
<i>Staphylococcus aureus</i>	+	1	9	NT	20.39 (8 d)	NT			[29]
<i>Staphylococcus carnosus</i>	+	1	9	NT	21.2 (8 d)	NT			[29]

<i>Salmonella typhimurium</i>	-	1	9	NT	28.02 (12 d)	NT			[29]
<i>Pseudomonas fluorescens</i>	-	1	9	NT	7.17 (12 d)	NT			[29]
<i>Listeria monocytogenes</i>	+	1	9	NT	53.2 (21 d, 21°C)	NT			[93]
<i>Salmonella</i>	-	1	9	NT	59.9 (21 d, 21°C)	NT			[93]